Table 5. Relative risk and attributable risk proportion for anti-TB treatment between ATLI and non-ATLI anti-TB treatment cases.a .
| Result | |||||
| Category | Subcategory | ATLI | Non-ATLI | RR (95% CI) | AR %d (95% CI) |
| Intensive treatment phaseb | Prolonged | 17 (16.19%) | 323 (7.71%) | 2.11 (1.23, 3.60) | 52.51 (18.81, 72.22) |
| Un-prolonged | 88 (83.81%) | 3864 (92.29%) | |||
| Smear result at 2 monthsc | Negative converted | 94 (91.26%) | 3929 (94.54%) | 1.56 (0.77, 3.17) | 35.91 (−30.35, 68.48) |
| Un-negative converted | 9 (9.74%) | 227 (5.46%) | |||
| Clinical treatment outcome | Unsuccessful outcomese | 16 (15.09%) | 67 (1.60%) | 9.25 (5.69,15.05) | 89.19 (82.42, 93.36) |
| Successful outcomesf | 90 (84.91%) | 4131 (98.40%) | |||
a
Abbreviation used in table: TB, tuberculosis; ATLI, Anti-tuberculosis Drug Induced Liver Injury; RR, relative risk; AR%: attributable risk proportion.
b
Intensive treatment phase: the number of patients was 4292, because 12 patients missed data.
c
Smear result at 2 months: the number of patients was 4259, because 45 patients missed smear examination.
d
AR%: it is the percent of the incidence of an outcome in the exposed that is due to the exposure.
e
Unsuccessful outcomes: A sum of treatment failure, died, default and transfer out.
f
Successful outcomes: A sum of cure and treatment completed.